Patient-reported outcomes
sleep disturbance, itch
There were no differences in the VAS scores for itch intensity and sleep disturbance due to itch across treatment groups. For patients who responded to the global PGIS questionnaire, results at weeks 12, 24, and 48 were similar to those at baseline across all treatment groups; most patients rated their symptoms as very mild, mild, or moderate. In patients who responded to the PGIC questionnaire, most in the CVC and TXR